CHMP again negative on Avastin for Brain Cancer - Roche
The Committee for Medicinal Products for Human Use has issued a negative opinion on Avastin (bevacizumab) from Roche, for Glioblastoma, in combination with radiation and temozolomide. Roche had presented data from one main trial of 921 patients and the CHMP noted that "although there was an improvement in progression-free survival, it could not be considered clinically relevant because of limitations in the methods available to measure the size of brain tumours".
In addition, the CHMP noted, there was no improvement in overall survival so has decided that the benefits of Avastin for glioblastoma do not outweigh its risk. The drug is already approved in the USA and Japan for the disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.